Research field: Dendritic cells and Cancer Immunotherapy
The mission of the Laoui lab is to constantly improve our understanding of the immune compartment in tumors with a particular focus on dendritic cells to develop novel cancer therapies against tumor progression, tumor relapse and metastasis. More specifically, we use the heterogeneity of tumor-derived conventional dendritic cells (cDCs) as a target for therapeutic intervention. Our research has enabled us to uncover the genetic, phenotypic and functional characteristics of immune cell subpopulations in different activation states in the tumor microenvironment. As such, we have identified and characterized different cDC subpopulations in the tumor and proven their utility as a novel cell-based cancer therapy. Our ongoing projects focus on further improving cDC therapy, bringing it to the clinic as well as increasing the fundamental understanding of their activity and their interaction with other cell types within the tumor microenvironment (TME). These projects allowed us to build and expand our expertise in orthotopic cancer models for breast, lung and ovarian cancer and analysis techniques such as single cell RNA-seq, CITE-seq, advanced flow cytometric analysis and spatial transcriptomics as well as functional ex-vivo and in vitro assays.
Area of expertise
Technology transfer potential